Right Ventricular and Right Atrial Function Are Less Compromised in Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction: A Comparison With Pulmonary Arterial Hypertension With Similar Pressure Overload.

"Disclosures Dr Handoko serves on advisory boards for Novartis, Boehringer Ingelheim, Vifor Pharma, AstraZeneca, Bayer, MSD, and Quin. He has also received education and research grants from Novartis, Boehringer Ingelheim, and Vifor Pharma, which were paid to his employer."

"Sources of Funding This research was financially supported by the Netherlands Organization for Scientific Research: NWO-VICI No. 918.16.610 (Dr Vonk Noordegraaf) and NWO-VIDI No. 917.18.338 (Dr de Man). The work was also funded by Dutch Heart Foundation Dekker senior post doctorate grant No. 2018T059 (J. van Wezenbeek and Dr de Man), Dekker Senior Clinical Scientist grant No. 2020T058 (Dr Handoko), and the Netherlands CardioVascular Research Initiative: CVON-2017-10 DOLPHIN-GENESIS (Drs Vonk Noordegraaf, de Man, Jan Bogaard, and José Goumans) and CVON-2018-29 PHAEDRA-IMPACT (Drs Vonk Noordegraaf, de Man, Jan Bogaard, and José Goumans)."